Proceedings of the National Academy of SciencesGenetic & Genomic MedicinePeer-reviewed journal article
Deciphering the causal relationship between blood metabolites and Alzheimers Disease: a Mendelian Randomization study
Jodie LordiD, Bradley S. JermyiD, Rebecca GreeniD, Andrew WongiD, Jin XuiD, Cristina Legido‐QuigleyiD, Richard DobsoniD, Marcus RichardsiD, Petroula ProitsiiD
Abstract
There are currently no disease modifying treatments for Alzheimers Disease (AD). Epidemiological studies have highlighted blood metabolites as potential biomarkers, but possible confounding and reverse causation prevent causal conclusions. Here, we investigated whether nineteen metabolites previously associated with midlife cognitive function, are on the causal pathway to AD. Summary statistics from the largest Genome-Wide Association Studies (GWAS) for AD and for metabolites were used to perform bi-directional univariable Mendelian Randomisation (MR). Bayesian model averaging MR (MR-BMA) was additionally performed to address high correlation between metabolites and to identify metabolite combinations which may be on the AD causal pathway. Univariable MR indicated three Extra-Large High-Density Lipoproteins (XL.HDL) to be on the causal pathway to AD: Free Cholesterol (XL.HDL.FC: OR=0.86, 95% CI=0.78-0.94), Total Lipids (XL.HDL.L: OR=0.88, 95% CI=0.80-0.97), and Phospholipids (XL.HDL.PL: OR=0.87, 95% CI=0.81-0.97); significant at an adjusted threshold of p<0.009. MR-BMA corroborated XL.HDL.FC to be amongst the top three causal metabolites, additionally to Total Cholesterol in XL.HDL (XL.HDL.C) and Glycoprotein Acetyls (GP) (posterior probabilities=0.112, 0.113, 0.287 respectively). Both XL.HDL.C and GP also demonstrated suggestive evidence of univariable causal associations (XL.HDL.C:OR=0.88, 95% CI=0.79-0.99; GP:OR=1.2, 95% CI=1.05-1.38); significant at the 5% level. This study offers insight into the causal relationship between metabolites previously demonstrating association with mid-life cognition, and AD. It highlights GP in addition to several XL.HDLs as causal candidates which warrant further investigation. As the pathological changes underpinning AD are thought to develop decades prior to symptom onset, progressing these findings could hold special value in informing future risk reduction strategies.
- organism: human
- assay: GWAS summary statistics
- research focus: GWAS / association mapping
- approach: statistical model
- Citations
- 63
- FWCI
- 8.42
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Causal associations between potentially modifiable risk factors and the Alzheimer's phenome: A Mendelian randomization study
Shea J. Andrews, Brian Fulton‐Howard, … Alison Goate·Annals of NeurologyPeer-reviewed·Sep 29, 2020
- Association between alcohol consumption and Alzheimer’s disease: A Mendelian randomization Study
Shea J. Andrews, Alison Goate, Kaarin Jane Anstey·Alzheimer s & DementiaPeer-reviewed·Nov 27, 2019
- Effects of genetic liability to Alzheimers disease on circulating metabolites across the life course
Hannah Compton, Madeleine L. Smith, … Emma Louise Anderson·medRxiv·Mar 24, 2022
- The causes and consequences of Alzheimer's disease: phenome-wide evidence from Mendelian randomization
Roxanna Korologou‐Linden, Laxmi Bhatta, … Neil M Davies·Nature CommunicationsPeer-reviewed·Aug 11, 2022
- Causal relationship of cerebrospinal fluid biomarkers with the risk of Alzheimer’s disease: A two-sample Mendelian randomization study
Soyeon Kim, Kiwon Kim, … Hong‐Hee Won·Journal of Alzheimer s DiseasePeer-reviewed·Feb 25, 2021
- Assessing genetic overlap and causality between blood plasma proteins and Alzheimer's Disease
Álex Handy, on behalf of the Alzheimer’s Disease Neuroimaging Initiative, … Petroula Proitsi·Journal of Alzheimer s DiseasePeer-reviewed·Aug 27, 2021